Losartan

Losartan has been studied in 72 papers since 1996: 11 trials and 11 observational studies in people, 39 in animals, 2 in cells, 6 reviews; 19 in the past year. It is an approved medicine. The newest story, Oct 20, 2026: “Kidney-related high blood pressure damaged white matter in rats”.

InterventionApproved 1995

72 papers study it22 more mention it77 findingsUpdated

PubChemChEBIMeSH

4 new papers in 30 daysSee all 94 papers on losartan

At a glance

Losartan extends lifespan in rat and mouse studies, while independent labs reproduce prevention of senescence in cells. One group reports reduced frailty in prefrail people in a human trial, but another trial shows no clear walking-speed effect; rat blood-pressure results also differ. Companies developing losartan sponsor some trials across its uses.

77 findings in 41 papers from 2007 to 2026, 3 of them since April 2026

The findings reach people, from one lab or study; independent labs found the same change in cells and mice. 27 independent labs in 15 countries; 230 trials, 9 about aging, 100 with no results posted.

“There was no effect of losartan (difference of means = -0.065 ± 0.116 [SE], 95% confidence interval [CI]: -0.293-0.163, p = .58)”
Effect of Losartan and Fish Oil on Plasma IL-6 and Mobility in Older Persons. The ENRGISE Pilot Randomized Clinical TrialThe journals of gerontology. Series A, Biological sciences and medical sciences2018doi:10.1093/gerona/gly277

1 of its findings points the other way.

Cells and mice: replicated by independent labs. Humans: a single group. Worms or flies: nothing yet.
  • 27 independent labs in 15 countries
  • 1 finding against
  • 230 trials, 9 about aging, 100 with no results posted
  • Funders: National Institutes of Health and others
  • 22 of 230 trials sponsored by its developers
  • Human trial11
  • Humans11
  • Animals39
  • Cells2
  • In silico1

6 studies gave losartan to people and measured what changed.

What changedDesignPeopleSource

up: Increases CAF

Randomized trial16 weeks58 peoplemales≥ 64 years of ageOlder adultsJournal of cachexia, sarcopenia and muscle, Jun 1, 2025

down: Decreases frailty89% lower odds (95% CI: 18% to 99% lower odds, p = .03)

down: Decreases frailty score0.3-point lower frailty score (95% CI: 0.01-0.5, p = .04)

Randomized trial6 months25 people70-90 yearsOlder adults; The oldest old; prefrailThe journals of gerontology. Series A, Biological sciences and medical sciences, May 6, 2022

no change: Has no effect on lymphoid tissue fibrosis

Randomized trial48 weeks48 peopleHIV medicine, Jul 20, 2021

no change: Has no effect on IL-6difference of means -0.065 ± 0.116 (SE); 95% CI -0.293 to 0.163; p = .58

no change: Has no effect on 400-m walking speeddifference of means -0.025 ± 0.026 (SE) m/s; 95% CI -0.076 to 0.026; p = .34

Randomized trial12 months289 peopleBoth≥70 yearsOlder adults; log-transformed plasma IL-6The journals of gerontology. Series A, Biological sciences and medical sciences, Dec 13, 2018

no change: Has no effect on muscle cross-sectional area

no change: Has no effect on quadriceps peak force

Randomized trial4 months58 peopleMen65 years and olderOlder adultsJournal of applied physiology (Bethesda, Md. : 1985), Aug 9, 2018

What did lifespan studies of losartan find?

DrugAge

DrugAge records 1 result from 1 paper: 1 in rats. Average lifespan is the mean or the median, as each paper reports it.

What did studies of losartan find?

65

Studies of losartan measured 65 outcomes; the most studied are cellular senescence (4 studies), lifespan (2) and blood pressure (2).

Cellular senescence

downin human cells2downin pig cells2

4 studies
  1. Losartan decreases cellular senescence in human cells (low dose, in human BM-MSCs).

    Cellslow dose, in human BM-MSCslow dose24 h

  2. Losartan decreases cellular senescence in human cells.

    Cellskidney

  3. Losartan decreases cellular senescence in pig cells (against the thrombin-induced pro-senescence response).

    Cellsagainst the thrombin-induced pro-senescence responseatrial endothelial cells

  4. Losartan prevents cellular senescence in pig cells (microparticle-induced endothelial senescence).

    Cellsmicroparticle-induced endothelial senescence

More on Cellular senescence

Lifespan

upin mice1upin rats1

2 studies
  1. Losartan improves lifespan in mice (WT mice).

    AnimalsWT mice

  2. Losartan extends lifespan in rats (aging).

    Animalsaging30 mg.kg(-1).day(-1)n = 20

Blood pressure

downin mice1downin rats1

2 studies
  1. Losartan decreases blood pressure in rats (aged rats with established hypertension).

    Animalsaged rats with established hypertensionmales

  2. Losartan decreases blood pressure in Ercc1Δ/- mice.

    Animalsin Ercc1Δ/- micechronic

Oxidative stress and ROS signaling

downin rats2

2 studies
  1. Losartan decreases oxidative stress and ROS signaling in rats (spontaneously hypertensive rats compared with vehicle-treated rats).

    Animalsspontaneously hypertensive rats compared with vehicle-treated ratshippocampus10 mg/kg19 days

  2. Losartan decreases oxidative stress and ROS signaling in rats (aged rats with erectile dysfunction).

    Animalsaged rats with erectile dysfunctioncorpus cavernosum30 mg/kg4 weeksn = 10

More on Oxidative stress and ROS signaling

Serum metabolome aging signature

downin humans1downin mice1

1 study
  1. Losartan decreases serum metabolome aging signature in humans (pre-frail; phase 2 randomized placebo-controlled trial).

    Human trialpre-frail; phase 2 randomized placebo-controlled trialserummales

  2. Losartan decreases serum metabolome aging signature in mice.

    Animalsserummales

More on Serum metabolome aging signature

CAF

upin humans1

1 study
  1. Losartan increases CAF in humans.

    Human trialserum16 weeks

  2. Losartan increases CAF in humans (7%-9% increase at 16 weeks, p < 0.005).

    Human trial16 weeksmales

More on CAF

Mean blood pressure

no changein rats1downin rats1

1 study
  1. Losartan showed no clear effect on mean blood pressure in SHRs.

    Animalsin SHRsp.o.3 mg/kg18 weeksmales

  2. Losartan decreases mean blood pressure in SHRs.

    Animalsin SHRsp.o.10 mg/kg18 weeksmales

More on Mean blood pressure

Behavior

upin rats1

1 study
  1. Losartan improves behavior in rats (renovascular hypertension).

    Animalsrenovascular hypertension

    Kidney-related high blood pressure damaged white matter in rats

    medRxivPreprint

White matter pathology

downin rats1

1 study
  1. Losartan decreases white matter pathology in rats (renovascular hypertension).

    Animalsrenovascular hypertensionwhite matter

    Kidney-related high blood pressure damaged white matter in rats

    medRxivPreprint

Survival

upin mice1

1 study
  1. Losartan increases survival in mice (not a full lifespan analysis).

    Animalsnot a full lifespan analysismales

Frailty score

downin humans1

1 study
  1. Losartan decreases frailty score in humans (prefrail) (0.3-point lower frailty score (95% CI: 0.01-0.5, p = .04)).

    Human trialprefraildaily oralbeginning at 25 mg per day and increasing every 8 weeks6 monthsn = 25

More on Frailty score

Frailty

downin humans1

1 study
  1. Losartan decreases frailty in humans (prefrail) (89% lower odds (95% CI: 18% to 99% lower odds, p = .03)).

    Human trialprefraildaily oralbeginning at 25 mg per day and increasing every 8 weeks6 monthsn = 25

immune activation

no changein humans1

1 study
  1. Losartan showed no clear effect on immune activation in humans.

    Human trial48 weeks

Lymphoid tissue fibrosis

no changein humans1

1 study
  1. Losartan showed no clear effect on lymphoid tissue fibrosis in humans.

    Human triallymphoid tissue48 weeks

400-m walking speed

no changein humans1

1 study
  1. Losartan showed no clear effect on 400-m walking speed in humans (difference of means -0.025 ± 0.026 (SE) m/s; 95% CI -0.076 to 0.026; p = .34).

    Human trial50-100 mg/d12 months

All 65

What is losartan linked with?

2

Studies link losartan with 2 measures: gout and bone fracture.

Gout

downin humans1HR 0.904

1 study
  1. Losartan is linked with a lower risk of gout in humans (Newly diagnosed hypertension; combined with amlodipine; compared with non-persistent users) (HR 0.904, 95% CI 0.877–0.932).

    HumansNewly diagnosed hypertension; combined with amlodipine; compared with non-persistent users5 years

More on Gout

Bone fracture

upin humans1OR 3.28

1 study
  1. Losartan is associated with bone fracture in humans (patients presenting with falls) (OR 3.28; 95% CI: 1.48–7.26; p = 0.003).

    Humanspatients presenting with fallsn = 200

More on Bone fracture

What acts on losartan?

1

Studies name AGTR2 as acting on losartan.

AGTR2

is required forin mice1

1 study
  1. AGTR2 is required for losartan in mice (HALI lung-protective effects absent in AT2R-/y mice).

    AnimalsHALI lung-protective effects absent in AT2R-/y mice

More on AGTR2

Has losartan been tested in people?

9 of 230 about aging

Yes: 11 trials and 11 observational studies in people have been published, and 210 trials are registered.

Approved

  • FDA Cozaar

    Apr 14, 1995Hypertension, Stroke, Diabetic Nephropathy, high blood pressure

  • FDA Arbli

    Mar 13, 2025Hypertension, Stroke, Diabetic Nephropathy, high blood pressure

Repurposing

40 of 117

Every condition in trials

  • Camurati-Engelmann Syndrome

    Phase 3Status unknown3 trials

  • Respiratory distress syndrome

    Phase 3Terminated3 trials

  • Aortic coarctation

    Phase 3Recruiting1 trial

  • Mild to severe hypertension

    Phase 3Completed1 trial

  • Radiation Fibrosis Syndrome

    Phase 2Active, not recruiting2 trials

  • Hyperlipidemias

    Phase 2Results posted1 trial

All 20

Stopped

  • NCT02416102TerminatedChronic bronchitis

    Difficulty in recruitment

  • NCT04606563TerminatedRespiratory distress syndrome

    DSMC recommendation due to futility

  • NCT00981747TerminatedPulmonary fibrosis

    Funding was withdrawn.

  • NCT02373241TerminatedSickle cell anemia

    Estimated GFR was determined not to be a reliable endpoint for this study. We identified significant variabilty in annual eGFR that it became inappropriate to randomize to a medication but use EGFR as the primary endpoint.

  • NCT03206788TerminatedCystic fibrosis

    due to slow enrollment and approval of the Trikafta for CF patients

  • NCT00388388TerminatedPrehypertension

    Few subjects recruited, sponsor withdrew support.

All 12

Who is developing losartan?

3 companies: Organon, Boehringer Ingelheim and Laboratorios Silanes S.A. de C.V..

Companies
  • OrganonPhase 4hypertension, essential hypertension
  • Boehringer IngelheimPhase 4hypertension, diabetic nephropathies
  • Laboratorios Silanes S.A. de C.V.Phase 3essential arterial hypertension

Trial sponsors

Funding

2 grants since 2019

National Institute on Aging$90.6KSão Paulo Research Foundation

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Losartan extends lifespan in wild-type mice and reduces a serum metabolomic aging signature in aged mice; mitochondrial effects are absent in very old mice. Results come from one lab, without independent replication. Of 218 registered trials, 62 ended over a year ago without posted results or a citing paper.

  2. Summary written from the findings.

Latest

Dec 2025: 2Jan 2026: 0Feb 2026: 7Mar 2026: 1Apr 2026: 1May 2026: 1Jun 2026: 0Jul 2026: 1Aug 2026: 1Sep 2026: 1Oct 2026: 5Nov 2026: 222 papers in 12 months
medRxiv

Kidney-related high blood pressure damaged white matter in rats

About two-thirds of rats with kidney-related high blood pressure developed white matter lesions, which expanded between seven and nine weeks.About two-thirds of rats with kidney-related high blood pressure developed white matter lesions, which expanded between seven and nine weeks.

Preprint: rat study · 13 ratsKidney
Nature

Brown fat linked to less cardiovascular and psychiatric disease

An observational study of 101,243 patients at a large cancer center linked detectable brown fat to lower prevalence of cardiovascular and psychiatric diseases.An observational study of 101,243 patients at a large cancer center linked detectable brown fat to lower prevalence of cardiovascular and psychiatric diseases.

Case-control · 26,302 peopleMechanisms
medRxiv

Related blood pressure drugs linked to differing dementia risks

Compared with lisinopril, the drugs collectively had a dementia hazard ratio of 0.86, indicating a lower rate of new diagnoses over follow-up.Compared with lisinopril, the drugs collectively had a dementia hazard ratio of 0.86, indicating a lower rate of new diagnoses over follow-up.

Preprint: cohort studyIncident all-cause dementia

See all 94 papers on losartan